BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help

Search Results

Documents 1-25 out of 28 found
  Current Search:  pleural: 61, effusion: 1, malignant: 60     

HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the...

Montana's News Station:  Dec 29 2008 7:01PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the...

Kait 8:  Dec 29 2008 5:16PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Availability of Third MicroRNA-Based Diagnostic Test: miRview(TM) meso
Rosetta Genomics, Ltd.

(NASDQ: ROSG), announced the introduction of its third diagnostic test, miRview(TM) meso.

The test is now commercially available through Rosetta Genomics CLIA-certified lab in Philadelphia.

'I am very excited to...

Clinical Lab Products:  Dec 29 2008 5:01PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Clinical Lab Products:  Dec 29 2008 5:01PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer The Company Expects to Perform Approximately 2,000 Tests During 2009 in its Laboratory in Philadelphia, PA.

REHOVOT, Israel, JERSEY CITY, New Jersey and...

Breitbart.com:  Dec 29 2008 3:15PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the...

KSLA:  Dec 29 2008 2:59PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Houston Chronicle:  Dec 29 2008 2:38PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of...

PR Newswire via Yahoo!:  Dec 29 2008 2:36PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the...

KLFY:  Dec 29 2008 2:32PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Nashville Business Journal:  Dec 29 2008 2:27PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the...

KOTA Territory News:  Dec 29 2008 2:26PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Portland Business Journal:  Dec 29 2008 2:25PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Cincinnati Business Journal:  Dec 29 2008 2:22PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel To order the test, physicians may contact 1-888-522-7971, or visit the company's website http://www.rosettagenomics.com.

'I am very excited to finally see a molecularly-based test that can objectively differentiate...

Genetic Engineering News:  Dec 29 2008 2:21PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29, 2008 /PRNewswire-FirstCall via COMTEX/ -- ROSG | Quote | Chart | News | PowerRating -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of...

TradingMarkets:  Dec 29 2008 2:16PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Columbus Business First:  Dec 29 2008 2:16PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test:
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Forbes.com:  Dec 29 2008 2:14PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the introduction of its third diagnostic test, miRview(TM) meso.

The test is now commercially available through Rosetta...

The Business Journal Phoenix:  Dec 29 2008 2:13PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Biz Journals:  Dec 29 2008 2:06PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Street Insider:  Dec 29 2008 2:04PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
The Company now has Three Commercially Available Molecular Diagnostic Tests for Cancer The Company Expects to Perform Approximately 2,000 Tests During 2009 in its Laboratory in Philadelphia, PA.

REHOVOT, Israel, JERSEY CITY, New Jersey and...

PR Newswire:  Dec 29 2008 2:02PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, (News) Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

FinanzNachrichten.de:  Dec 29 2008 2:01PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

San Antonio Business Journal:  Dec 29 2008 1:55PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
'I am very excited to finally see a molecularly-based test that can objectively differentiate mesothelioma from several types of carcinomas in the lung with such high level of accuracy' noted Harvey Pass Malignant pleural...
NewsBlaze:  Dec 29 2008 1:46PM
Matching: pleural malignant
Find similar documents
HTML
57%
Rosetta Genomics Announces Commercial Availability of Its Third MicroRNA-Based Diagnostic Test: miRview(TM) me
REHOVOT, Israel, JERSEY CITY, New Jersey and PHILADELPHIA, Pennsylvania, December 29 /PRNewswire-FirstCall/ -- Rosetta Genomics, Ltd.

(NASDQ: ROSG), the leading developer of microRNA-based molecular diagnostics, announced today the...

Financials.com:  Dec 29 2008 1:45PM
Matching: pleural malignant
Find similar documents


 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.